Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation - Full Text View

Sponsored by:	Vanderbilt University
Information provided by:	Vanderbilt University
ClinicalTrials.gov Identifier:	NCT00608231

Purpose

To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery has no significant effect on electrophysiological parameters of DBS micro-electrode recordings

Condition	Intervention	Phase
Parkinson's Disease Essential Tremor Dystonia	Drug: Dexmedetomidine Hydrochloride Infusion Drug: Normal Saline	Phase II Phase III

Genetics Home Reference related topics: early-onset primary dystonia essential tremor familial paroxysmal nonkinesigenic dyskinesia Parkinson disease

MedlinePlus related topics: Dystonia Parkinson's Disease Surgery Tremor

Drug Information available for: Dexmedetomidine Dexmedetomidine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:

Micro-electrode Recordings [ Time Frame: Intra-operative ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Neurological Exam Findings [ Time Frame: Intra-operative ] [ Designated as safety issue: No ]

Estimated Enrollment:	90
Study Start Date:	January 2008
Estimated Study Completion Date:	January 2010
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
PD-STN: Experimental Parkinson's Disease -- STN target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of 1 During deep brain stimulator implantation surgery
PD - GPi: Experimental Parkinson's Disease -- GPi target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of 1 During deep brain stimulator implantation surgery
ET - VIM: Experimental Essential Tremor -- VIM target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of 1 During deep brain stimulator implantation surgery
Dystonia - GPi: Experimental Dystonia -- GPi target	Drug: Dexmedetomidine Hydrochloride Infusion Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of 1 During deep brain stimulator implantation surgery
PD - STN Control: Placebo Comparator Parkinson's Disease -- STN target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
PD - GPi Control: Placebo Comparator Parkinson's Disease -- GPi target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
ET - VIM Control: Placebo Comparator Essential Tremor -- VIM target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
Dystonia - GPi Control: Placebo Comparator Dystonia -- GPi target	Drug: Normal Saline Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery

Detailed Description:

Deep brain stimulator (DBS) implants are used in the treatment of medically refractory movement disorders such as Parkinson's disease, essential tremor and dystonia. Because of the uniqueness of each individual brain, the surgery to implant a DBS electrode requires detailed anatomic and physiological information for each patient. The anatomic data is obtained before surgery via a Magnetic Resonance Imaging (MRI) scan of the patient's brain.

Physiological data is obtained during the operation via micro-electrode recording of the patient's brain and neurological examination of the patient.

Therefore, DBS surgery can be uncomfortable to patients, as it can be very time consuming and requires the patient to be awake and attentive.

The specific aims of this project are:

To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery has no significant effect on electrophysiological parameters of DBS micro-electrode recordings.
To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery have no significant effects on neurological findings and/or patient cooperation during neurological examination.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Any patient who has agreed to undergo DBS implantation.

Exclusion Criteria:

Patients who fail recommendation for DBS surgery discussed in Vanderbilt University Movement Disorder Clinical Conference.
Patients not consented for DBS surgery.
Patients or legal guardians not able to provide informed consent.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00608231

Contacts

Contact: Joseph Neimat, M.D.	615-322-7417	joseph.neimat@Vanderbilt.Edu
Contact: Melba T. Isom	615-343-9822	melba.isom@vanderbilt.edu

Locations

United States, Tennessee
Vanderbilt University Medical Center	Recruiting
Nashville, Tennessee, United States, 37232

Sponsors and Collaborators

Vanderbilt University

Investigators

Principal Investigator:

Joseph Neimat, M.D.

Vanderbilt University

More Information

No publications provided

Responsible Party:	Vanderbilt University ( Joseph Neimat, M.D. )
Study ID Numbers:	070666
Study First Received:	January 7, 2008
Last Updated:	January 23, 2009
ClinicalTrials.gov Identifier:	NCT00608231 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Dystonic Disorders
Neurotransmitter Agents
Adrenergic Agents
Basal Ganglia Diseases
Dystonia
Brain Diseases
Neurodegenerative Diseases
Benign Essential Tremor Syndrome
Adrenergic Agonists
Signs and Symptoms
Movement Disorders
Hypnotics and Sedatives
Dexmedetomidine

Analgesics
Essential Tremor
Ganglion Cysts
Adrenergic alpha-Agonists
Central Nervous System Diseases
Central Nervous System Depressants
Dyskinesias
Tremor
Parkinson Disease
Analgesics, Non-Narcotic
Neurologic Manifestations
Parkinsonian Disorders
Peripheral Nervous System Agents

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Basal Ganglia Diseases
Physiological Effects of Drugs
Dystonia
Neurodegenerative Diseases
Brain Diseases
Adrenergic Agonists
Signs and Symptoms
Movement Disorders
Sensory System Agents
Therapeutic Uses
Hypnotics and Sedatives
Dexmedetomidine

Analgesics
Essential Tremor
Adrenergic alpha-Agonists
Nervous System Diseases
Central Nervous System Diseases
Central Nervous System Depressants
Dyskinesias
Pharmacologic Actions
Parkinson Disease
Analgesics, Non-Narcotic
Neurologic Manifestations
Parkinsonian Disorders
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009